Share This Author
STATs in cancer inflammation and immunity: a leading role for STAT3
Signal transducer and activator of transcription proteins are central in determining whether immune responses in the tumour microenvironment promote or inhibit cancer, and STAT3 is a promising target to redirect inflammation for cancer therapy.
The STATs of cancer — new molecular targets come of age
Tumour cells acquire the ability to proliferate uncontrollably, resist apoptosis, sustain angiogenesis and evade immune surveillance. STAT proteins — especially STAT3 and STAT5 — regulate all of…
Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Signal transducer and activator of transcription 3 (STAT3) propagates several levels of crosstalk between tumour cells and their immunological microenvironment, leading to tumour-induced immunosuppression and has emerged as a promising target for cancer immunotherapy.
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
It is shown that VEGF expression correlates with Stat3 activity in diverse human cancer cell lines and indicates that Stat3 represents a common molecular target for blocking angiogenesis induced by multiple signaling pathways in human cancers.
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
- Hua Yu, Heehyoung Lee, A. Herrmann, R. Buettner, R. Jove
- Biology, MedicineNature Reviews Cancer
- 1 November 2014
Well known for its role in tumour cell proliferation, survival, invasion and immunosuppression, JAK–STAT3 signalling also promotes cancer through inflammation, obesity, stem cells and the pre-metastatic niche.
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
It is shown that Stat3 is constitutively activated in diverse tumor-infiltrating immune cells, and ablating Stat3 in hematopoietic cells triggers an intrinsic immune-surveillance system that inhibits tumor growth and metastasis.
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
It is proposed that tumor Stat-3 activity can mediate immune evasion by blocking both the production and sensing of inflammatory signals by multiple components of the immune system.
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
- Lin Wang, T. Yi, M. Kortylewski, D. Pardoll, D. Zeng, Hua Yu
- BiologyThe Journal of experimental medicine
- 6 July 2009
The Th17 response can promote tumor growth, in part via an IL-6–Stat3 pathway, and adoptive transfer studies and analysis of the tumor microenvironment suggest that CD4+ T cells are the predominant source of IL-17.
Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity1
In vivo evidence is provided that the fundamental role of STAT3 signaling in autoimmunity relates to its absolute requirement for generating TH17 T cell responses, and STAT3 is a candidate target for TH17-dependent autoimmune disease immunotherapy that could selectively inhibit pathogenic immune pathways.
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells
It is shown that Src and JAK family tyrosine kinases cooperate to mediate constitutive Stat3 activation in the absence of EGF stimulation in model human breast cancer cell lines, suggesting that tyrosINE kinases transduce signals through Stat3 protein that contribute to the growth and survival of human breast cancers cells in culture and potentially in vivo.